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Background:  Low testosterone (T) is an independent predictor of reduced exercise capacity (EX) and poor clinical outcomes in pts with heart 
failure (HF). Modest sized trials have shown that T supplementation can improve EX in chronic HF pts.
Methods:  An extensive electronic and bibliographic search (1980 to Aug 1, 2010) was carried out. Eligible studies included randomized trials that 
reported the effects of T compared to placebo on EX in HF pts. Meta-analytic techniques endorsed by the Cochrane Collaboration were employed.
Results:  Four trials (n=198 pts, 84% male, mean age 67 yrs) were identified, that reported either the 6-minute walk test (6MWT), incremental 
shuttle walk test (ISWT) or peak VO2 to assess EX after up to 24 wks of treatment. T therapy was associated with significant improvement in EX as 
compared to placebo. The mean increase (95% CI) in the 6MWT, ISWT, and peak VO2 between the T and placebo groups were 54.0m (43.0-65.0), 
46.7m (12.6-80.9), and 2.70 ml/kg/min (2.68-2.72). The Fig shows T therapy was associated with a significant increase in EX measured by baseline 
standard deviations (net effect 0.52 SD, 95% CI 0.10-0.94). No significant adverse cardiovascular events were noted.
Conclusion: Given the broad confidence limits and unmet clinical needs, testosterone appears to be a promising novel therapy to improve EX in 
HF pts. Adequately powered RCT’s are now required to assess the benefits of testosterone in this high-risk population assessing quality of life, clinical 
events and safety.
